Ecromeximab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEcromeximab
Drug Alias Nameecromeximabum依美昔单抗KM-871KW-2871
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionGanglioside GD3 inhibitorsImmunostimulants
TargetsGanglioside GD3
Therapy Area/IndicationsSkin MelanomaMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsSkin MelanomaMelanoma

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG